GlassScriptPhysician profile
Zili He
NPI 1598709388
$31,690.78
in general payments reported to CMS, 2019-2025
62 companies · $5,257 in 2025
The $5,257 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,381 · 2020: $2,763 · 2021: $801 · 2022: $3,931 · 2023: $4,872 · 2024: $4,686 · 2025: $5,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,718 · Consulting Fee: $5,780 · Education: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,718.18 |
| Consulting Fee | $5,780.00 |
| Education | $1,316.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,915.09 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $3,624.21 | 2019-2025 | Tagrisso, Calquence, Imfinzi |
| Janssen Biotech, INC. | $3,582.89 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Celgene Corporation | $2,925.21 | 2019-2024 | Reblozyl, Pomalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,301.97 | 2019-2024 | Gilotrif |
| Puma Biotechnology, INC. | $1,965.78 | 2019-2024 | |
| Eisai INC. | $1,605.33 | 2020-2025 | |
| Exelixis INC. | $1,481.25 | 2020-2023 | Cabometyx |
| Abbvie INC. | $1,055.32 | 2021-2025 | |
| Incyte Corporation | $765.55 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $744.06 | 2020-2025 | Opdivo, Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $676.26 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $649.46 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $382.30 | 2019-2025 | |
| Foundation Medicine, INC. | $351.94 | 2019-2023 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $344.66 | 2019-2025 | |
| Pfizer INC. | $324.21 | 2019-2024 | |
| Amgen INC. | $323.87 | 2021-2024 | Evenity, Vectibix, Xgeva |
| Gilead Sciences, INC. | $323.36 | 2019-2024 | |
| Lilly USA, LLC | $301.17 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Beigene USA, INC. | $226.94 | 2021-2024 | Brukinsa |
| Genzyme Corporation | $205.32 | 2022-2025 | |
| Kite Pharma, INC. | $201.13 | 2022-2023 | Yescarta |
| Takeda Pharmaceuticals U.S.A., INC. | $195.71 | 2021-2025 | Ninlaro, Fruzaqla |
| Taiho Oncology, INC. | $163.26 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $145.10 | 2022 | |
| Alexion Pharmaceuticals, INC. | $130.05 | 2025 | Ultomiris |
| Alkermes, INC. | $130.00 | 2025 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2022 | |
| Neurocrine Biosciences, INC. | $125.00 | 2025 | |
| Axsome Therapeutics, INC. | $125.00 | 2023 | Auvelity |
| Daiichi Sankyo INC. | $124.81 | 2022-2025 | Enhertu, Datroway |
| Emd Serono, INC. | $121.86 | 2022-2024 | Tepmetko, Bavencio |
| Genmab U.S., INC. | $90.27 | 2023-2025 | Tivdak |
| Mirati Therapeutics, INC. | $71.05 | 2023-2024 | Krazati |
| Tesaro, INC. | $66.41 | 2019 | |
| Sumitomo Pharma America, INC. | $64.24 | 2023-2024 | Orgovyx |
| Accord Healthcare, INC. | $59.30 | 2025 | |
| Stemline Therapeutics INC. | $53.25 | 2024-2025 | Orserdu |
| Sobi, INC | $52.86 | 2023-2024 | |
| Deciphera Pharmaceuticals INC. | $49.79 | 2024-2025 | Qinlock, Romvimza |
| Pharmacosmos Therapeutics INC. | $49.23 | 2024 | Cosela |
| Iridex Corporation | $38.18 | 2019 | |
| Array Biopharma INC | $36.54 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| Seagen INC. | $30.88 | 2023 | Padcev |
| Ipsen Biopharmaceuticals, INC | $27.79 | 2025 | Onivyde |
| Janssen Pharmaceuticals, INC | $25.72 | 2019 | |
| Blueprint Medicines Corporation | $24.95 | 2023 | Ayvakit |
| Pharmaessentia USA Corporation | $24.90 | 2024 | Besremi |
| Telix Pharmaceuticals | $24.42 | 2024 | Illuccix |
| G1 Therapeutics, INC. | $23.88 | 2023 | Cosela |
| Azurity Pharmaceuticals, INC. | $23.03 | 2025 | Danziten |
| Helsinn Therapeutics (U.S.), INC. | $22.78 | 2019 | |
| Geron Corporation | $22.03 | 2025 | Rytelo |
| Glaxosmithkline, LLC. | $21.69 | 2024 | Ojjaara |
| Agios Pharmaceuticals, INC. | $20.27 | 2025 | Pyrukynd |
| Coherus Oncology, INC. | $19.94 | 2024 | |
| Novocure INC. | $18.06 | 2025 | Optune Lua (Novottf-200t) |
| Menarini Silicon Biosystems, INC. | $17.24 | 2024 | |
| Jazz Pharmaceuticals INC. | $17.09 | 2025 | |
| Myovant Sciences INC. | $17.03 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.89 | 2025 | Alymsys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zili He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.